Gilead Sciences Inks $11.9B Deal For Kite Pharma
Gilead Sciences Inc. will buy Kite Pharma Inc. in a deal that values its fellow California-based biopharmaceutical company at $11.9 billion, strengthening Gilead's position in the emerging space of cell therapy,...To view the full article, register now.
Already a subscriber? Click here to view full article